Application
News
www.shimadzu.com/an/
Shimadzu Corporation
© Shimadzu Corporation, 2025
For Research Use Only. Not for use in diagnostic procedures.
This publication may contain references to products that are not available in your country. Please contact us to check the availability of these
products in your country.
The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu.
See http://www.shimadzu.com/about/trademarks/index.html for details.
Third party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not
they are used with trademark symbol “TM” or “”.
Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.
The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its
accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the
use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject
to change without notice.
Nexera, and Shim-pack Velox are trademarks of Shimadzu Corporation or its affiliated companies in Japan and/or other countries.
Concentration (µg/mL)
1st
Analysis
2nd
Analysis
3rd
Analysis
4th
Analysis
5th
Analysis
Accuracy
%
RSD%
98.6 92.2 95.7 97.1 98.4 96.4 2.4
228.0>148.0 (+)
230.0>148.0 (+)
Table 2 Accuracy and repeatability of spiked EG in blood
<References>
1) S Shen, F Zhang, S Zeng, J Zheng, “An approach based on liquid
chromatography/electrospray ionization–mass spectrometry to
detect diol metabolites as biomarkers of exposure to styrene
and 1,3-butadiene,” Analytical Biochemistry, 386 (2009), p.186-
193
Conclusion
This article describes a simple and quick sample pretreatment
procedure for quantifying levels of ethylene glycol in blood.
When phenylboronic derivatives are used to measure ethylene
glycol by GC-MS, the derivatization reagent can accumulate in
the equipment, affecting subsequent measurements. However,
with the new method, the LC flow lines (including the
autosampler) can be cleaned with solvents that have a high
affinity for BPBA, which eliminates derivatization reagent
carryover.
The mobile phases used with this method are also used in
Shimadzu’s method package products, such as the “LC/MS/MS
Rapid Toxicology Screening System”. Therefore, with just a
column change, toxicological drug screening and ethylene
glycol measurements can both be performed with the same
system.
Y = 0.0365620X + 0.177183
R = 0.99996
0 50 100 150 200 250 300 350 400 450
0.0
2.5
5.0
7.5
10.0
12.5
15.0
17.5
20.0
500
PD-BPBA
0 0.5 1.0 1.5
0
1.0e4
2.0e4
3.0e4
4.0e4
270.0>184.0 (+)
272.0>186.0(+)
Fig. 4 MRM Chromatograms for EG-BPBA (10 µg/mL) and PD-BPBA
Fig. 5 Calibration Curve
Fig. 6 High Concentration Ethylene Glycol Analysis after Multiple Successive
Measurements
Evaluation of Linearity and Sensitivity
Reference samples of aqueous solutions of ethylene glycol were
analyzed to verify the linearity of the method. Given that
ethylene glycol is toxic at blood concentrations of 200 µg/mL
and above, reference samples of 10, 20, 50, 100, 200, and
500 µg/mL were prepared for analysis. Fig. 4 shows
chromatograms of EG-BPBA (10 µg/mL) and PD-BPBA. The
reference sample results show that the method is sensitive
enough to detect ethylene glycol at 1/20 of the level that is
toxic. The calibration curve is shown in Fig. 5. The results
showed good linearity (R = 0.99996).
A solution of ethylene glycol (1000 µg/mL) without BPBA that
was analyzed after verifying its linearity produced a
chromatogram with no EG-BPBA peak (Fig. 6). This indicates
that BPBA is unlikely to remain in equipment flow lines and
affect subsequent analyses.
Validity Assessment with Spiked Whole
Blood Sample
Ethylene glycol was added to whole blood to a concentration of
100 µg/mL and used to evaluate the repeatability and accuracy
(n = 5) of the method. The results showed good accuracy
(96.4 %) and repeatability (2.4 %) (Table 2). Analysis of a blank
whole blood sample with no added ethylene glycol resulted in a
peak with 1/20 the intensity of the 10 µg/mL reference solution
(Fig. 7).
0.5 1.0 1.5
0
2.0e4
4.0e4
6.0e4
8.0e4
0
0.0 0.5 1.0 1.5
0.0e0
2.0e2
4.0e2
6.0e2
8.0e2
1.0e3
0.0 0.5 1.0 1.5
5.0e4
1.0e5
1.5e5
2.0e5
EG-BPBA
0.0 0.5 1.0 1.5
0.0e0
1.0e2
2.0e2
3.0e2
4.0e2
5.0e2
6.0e2
228.0>148.0 (+)
230.0>148.0 (+)
EG-BPBA
228.0>148.0 (+)
230.0>148.0 (+)
Fig. 7 MRM Chromatograms Showing EG-BPBA in Blank
and Spiked Whole Blood (100 µg/mL)
Sample Concentration (µg/mL)
Relative Intensity
228.0>148.0 (+)
230.0>148.0 (+)
Blank
Spiked Whole
Blood
First Edition: Nov. 2025 01-01041-EN